These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 21917607)

  • 1. Novel therapies for metastatic castrate-resistant prostate cancer.
    Dayyani F; Gallick GE; Logothetis CJ; Corn PG
    J Natl Cancer Inst; 2011 Nov; 103(22):1665-75. PubMed ID: 21917607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel molecular targets for the therapy of castration-resistant prostate cancer.
    Agarwal N; Sonpavde G; Sternberg CN
    Eur Urol; 2012 May; 61(5):950-60. PubMed ID: 22209376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes.
    Galsky MD; Small AC; Tsao CK; Oh WK
    CA Cancer J Clin; 2012; 62(5):299-308. PubMed ID: 22535487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic hormone refractory prostate cancer: recent advances in standard treatment paradigm, and future directions.
    Keizman D; Maimon N; Gottfried M
    Am J Clin Oncol; 2014 Jun; 37(3):289-96. PubMed ID: 22772426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: novel therapies for metastatic castrate-resistant prostate cancer.
    Sartor O; Parker C
    J Natl Cancer Inst; 2012 May; 104(9):717; author reply 717. PubMed ID: 22440684
    [No Abstract]   [Full Text] [Related]  

  • 7. [Castration resistant prostate cancer 2011].
    Miller K
    Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New drugs in metastatic castration-resistant prostate cancer].
    Albiges L; Loriot Y; Gross-Goupil M; de La Motte Rouge T; Blesius A; Escudier B; Massard C; Fizazi K
    Bull Cancer; 2010 Jan; 97(1):149-59. PubMed ID: 20022854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel and bone-targeted agents for CRPC.
    Fizazi K; Albiges L; Massard C; Escudier B; Loriot Y
    Ann Oncol; 2012 Sep; 23 Suppl 10():x264-7. PubMed ID: 22987974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b.
    Karlou M; Lu JF; Wu G; Maity S; Tzelepi V; Navone NM; Hoang A; Logothetis CJ; Efstathiou E
    Prostate; 2012 Nov; 72(15):1638-47. PubMed ID: 22457212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of docetaxel failures in metastatic castrate-resistant prostate cancer.
    Pal SK; Lewis B; Sartor O
    Urol Clin North Am; 2012 Nov; 39(4):583-91. PubMed ID: 23084533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A renaissance in the medical treatment of advanced prostate cancer.
    Rove KO; Flaig TW
    Oncology (Williston Park); 2010 Dec; 24(14):1308-13, 1318. PubMed ID: 21294475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
    Payne H; Bahl A; Mason M; Troup J; De Bono J
    BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.
    Gu L; Liao Z; Hoang DT; Dagvadorj A; Gupta S; Blackmon S; Ellsworth E; Talati P; Leiby B; Zinda M; Lallas CD; Trabulsi EJ; McCue P; Gomella L; Huszar D; Nevalainen MT
    Clin Cancer Res; 2013 Oct; 19(20):5658-74. PubMed ID: 23942095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].
    Ouzaid I; Ravery V; Pouessel D; Culine S
    Prog Urol; 2013 Jan; 23(1):1-7. PubMed ID: 23287477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.
    Su Y; Liu Y; Behrens CR; Bidlingmaier S; Lee NK; Aggarwal R; Sherbenou DW; Burlingame AL; Hann BC; Simko JP; Premasekharan G; Paris PL; Shuman MA; Seo Y; Small EJ; Liu B
    JCI Insight; 2018 Sep; 3(17):. PubMed ID: 30185663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.
    Courtney KD; Taplin ME
    Curr Opin Oncol; 2012 May; 24(3):272-7. PubMed ID: 22327837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bone-targeted treatment in prostate cancer].
    Géczi L; Sinkovics I
    Magy Onkol; 2014 Sep; 58(3):199-203. PubMed ID: 25260084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells.
    Ketola K; Kallioniemi O; Iljin K
    PLoS One; 2012; 7(12):e51470. PubMed ID: 23251544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.